๐
Korjuny
catumaxomab
Ascites
โ
Authorised
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny